FreeFlow Percutaneous Atrial Septal Shunt for IPAH

Prior treatment

• Patients with contraindications to antiplatelet, coagulant or thrombotic therapy;
• Have participated in other drug or device clinical trials during the same period;

Other illness

• Local or systemic sepsis or other acute infection;
• Allergy to nickel and/or titanium and/or nickel/titanium-based materials;
• The patient had malignant arrhythmia;
• The patient did not receive standardized drug therapy (triple sequential therapy) according to the Chinese guidelines for the diagnosis and treatment of pulmonary hypertension within 3 months;
• Severe restrictive or obstructive lung disease;
• The anatomical structure of the heart is abnormal, and the shunt cannot be implanted on the atrial septum;

Lab values

• Glomerular filtration rate (GFR) \< 50 mL/min;
• Patients with severe liver dysfunction (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 times the upper limit of normal);
• Left ventricular ejection fraction (LVEF) \<50%;

Other

• Severe coagulopathy;
• Intolerance to contrast media;
• Women who are pregnant, planning to become pregnant (within 12 months) or breastfeeding;
• Implanted atrial septal defect (ASD)/ patent foramen ovale (PFO) closure device;
• SpO2 \< 90% without oxygen inhalation (pulse measurement);
• Other circumstances in which the patient was deemed by the investigator to be ineligible for inclusion in the trial.

• 18≤ age ≤70 years old, female or male;
• 10 mmHg≤ mean right atrial pressure (mRAP) ≤20 mmHg;
• The subjects had severe idiopathic pulmonary hypertension (mean pulmonary arterial pressure \> 45 mmHg);
• WHO grade III or IV;
• NT-proBNP≥650 ng/L;
• The subjects were informed of the nature of the study and agreed to all the requirements for participating in the study. They signed the informed consent form and agreed to complete the follow-up and the examinations required for the follow-up.